Opendata, web and dolomites

MEPHOS SIGNED

Shaping the Mechano-Pharmacological properties of Microparticles and Extracellular Vesicles for the Treatment of Osteoarthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEPHOS project word cloud

Explore the words cloud of the MEPHOS project. It provides you a very rough idea of what is the project "MEPHOS" about.

stem    bridge    translation    chemokine    clinic    intersectoral    ambition    billion    cell    metalloproteinase    chronic    symptoms    market    context    vesicles    boundaries    societal    weeks    secondments    fabrication    sustainably    polymeric    academic    hit    bone    options    osteoarthritis    adults    subchondral    small    treatment    obesity    characterization    training    fluid    degeneration    rationally       strategy    synovial    clinically    tissue    disability    culture    consequently    aging    extracellular    upl    approved    pain    regeneration    risk    deposition    single    rational    ultimately    scientists    assays    viscoelastic    modulating    stanford    geometry    gender    industrial    biologicals    replacement    preclinical    technologies       people    pharmacological    instil    upls    hydrogel    inclusion    clinical    sole    inhibitors    halt    translational    match    vitro    documents    articular    simultaneously    glycoproteins    2026    older    joint    million    action    sme    course    option    biological    continues    rising    2016    burden    microplates    oa    mephos    molecules    cartilage    sophisticated    release    curing    trauma    mechanical    disease    spark    interdisciplinary    predicted    realizing    models   

Project "MEPHOS" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 952˙200 €
 EC max contribution 864˙800 € (91%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2019
 Funding Scheme MSCA-RISE
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 312˙800.00
2    UNIVERSIDAD DE NAVARRA ES (PAMPLONA) participant 253˙000.00
3    UNIVERSIDADE DO MINHO PT (BRAGA) participant 225˙400.00
4    LIPOCURE LTD IL (JERUSALEM) participant 73˙600.00
5    BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY US (STANFORD) partner 0.00
6    THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL US (CHAPEL HILL) partner 0.00
7    University of Arkansas US (Fayetteville) partner 0.00
8    VANDERBILT UNIVERSITY US (NASHVILLE TENESSEE) partner 0.00

Map

 Project objective

Osteoarthritis (OA) is a chronic disease involving the degeneration of articular cartilage and subchondral bone. It represents the single most common cause of disability in older adults. Being aging, obesity, trauma and gender risk factors for OA, its societal burden is rapidly rising. Across EU, over 40 million people are affected by OA. Current treatment options aim at modulating the symptoms rather than curing this chronic disease. Consequently, joint replacement continues to be ultimately the sole option. In this context, MEPHOS aims at realizing an integrated strategy for OA treatment based on the intra-articular deposition of hydrogel, polymeric microplates (uPLs) that could simultaneously provide a long-term pharmacological action and mechanical support. To this end, the uPL geometry and mechanical properties will be rationally selected to match the viscoelastic behaviour of cartilage and synovial fluid. Over the course of several weeks, uPLs will sustainably release clinically-approved molecules for pain management and novel small molecules and biologicals; including chemokine and metalloproteinase inhibitors to halt tissue degeneration; glycoproteins, growth factors and stem cell-derived extracellular vesicles to favour tissue regeneration. MEPHOS involves three EU Academic Institutions and a SME for uPL fabrication, and four US Academic Institutions for uPL biological and preclinical characterization. Through interdisciplinary and intersectoral secondments, this project will support the training of EU scientists on sophisticated in-vitro assays and three different preclinical OA models; foster the rational development of uPLs; and instil a translational research culture to bridge preclinical-clinical boundaries. The inclusion of a SME and the Stanford SPARK Translation program documents MEPHOS ambition to develop technologies that could hit the clinic and an industrial market, which is predicted to growth from $1.6 billion in 2016 to $3.5 billion by 2026.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEPHOS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEPHOS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More  

iGame (2019)

Multi-dimensional Intervention Support Architecture for Gamified eHealth and mHealth Products

Read More  

DCPM (2020)

Digitalized Clone for Personalized Medicine

Read More